{"id":"NCT02986139","sponsor":"Amgen","briefTitle":"Study to Assess the Injection Site Pain Associated With a New Etanercept Formulation in Adults With Rheumatoid Arthritis or Psoriatic Arthritis","officialTitle":"A Multicenter, Randomized, Double-blind, Crossover Study to Assess the Injection Site Pain Associated With a Modified Etanercept Formulation in Adult Subjects With Either Rheumatoid Arthritis or Psoriatic Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-11-29","primaryCompletion":"2017-09-08","completion":"2017-10-09","firstPosted":"2016-12-08","resultsPosted":"2018-10-31","lastUpdate":"2019-07-18"},"enrollment":111,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"QUADRUPLE","primaryPurpose":"SUPPORTIVE_CARE"},"conditions":["Arthritis, Rheumatoid; Arthritis, Psoriatic"],"interventions":[{"type":"DRUG","name":"Commercial Formulation Etanercept","otherNames":["Enbrel"]},{"type":"DRUG","name":"New Formulation Etanercept","otherNames":[]}],"arms":[{"label":"Sequence AB","type":"EXPERIMENTAL"},{"label":"Sequence BA","type":"EXPERIMENTAL"}],"summary":"The primary objective was to assess the injection site pain associated with the new formulation of etanercept compared with commercial etanercept in adults with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) as measured by a visual analog scale (VAS).","primaryOutcome":{"measure":"Injection Site Pain","timeFrame":"Immediately following injection of each study drug on day 1 and day 8 of this crossover study","effectByArm":[{"arm":"Etanercept Commercial Formulation","deltaMin":23.6,"sd":22.3},{"arm":"Etanercept New Formulation","deltaMin":19.8,"sd":22.5}],"pValues":[{"comp":"OG000 vs OG001","p":"0.048"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":23},"locations":{"siteCount":30,"countries":["United States","Puerto Rico"]},"refs":{"pmids":["30915626"],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":106},"commonTop":["Injection site reaction","Pain in extremity","Hypoaesthesia","Injection site erythema","Rash"]}}